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Abstract
Background:  Conflicting data exist about the prevalence of HER-2/neu overexpression in
colorectal cancer ranging from 0 to 83 %. In our study we tried to clarify the extent of expression
and its relationship to clinicopathological parameters.
Methods: This study involved 77 specimens of malignant colorectal cancer lesions of surgically
resected patients. HER-2/neu immunohistochemistry was performed using the Hercep-Test Kit.
Results: Out of 77 specimens, 56 were Her-2/neu negative (70%), 20 (26%) showed a barely
immunostaining (1+), only 1 (1%) was moderately (2+) and 2 (3%) were strongly positive (3+). Her-
2/neu staining (moderately and strongly positive) was only detected in primary tumours of patients
with confirmed metastases. No relationship was found between membranous HER-2 expression
and patients' gender or differentiation. The median survival time of patients with positive HER-2/
neu immunostaining was 21 versus 39 months in patients without HER-2/neu expression (p =
0.088).
Conclusion: The c-erbB protein expression was observed in colorectal cancer but rarely in the
therapeutic range (2+ and 3+). There was no significant association with tumour grade, gender,
localization of the primary tumour or survival. These data indicate that c-erbB-2 is unlikely to play
a major role in the therapeutic management of colorectal cancer.
Background
Colorectal cancer (CRC) is one of the most common
malignancies in the western world [1]. The development
of new cytotoxic agents (e.g. oxaliplatin and irinotecan)
and surgical techniques have improved survival of
patients with CRC. Once a patient becomes refractory to
modern chemotherapeutic regimens no further treatment
options are available. Recently the therapeutic armamen-
tarium has been improved by the availability of mono-
clonal antibodies against the vascular endothelial – and
epidermal growth factor receptor [2].
Her-2/neu oncogene is also a member of the tyrosine
kinase family similar to the epidermal growth factor
receptor (EGFR), HER-1, HER-3 and HER-4. HER-2 is
located on chromosome 17q21 and encodes a 185 kD
transmembran protein that lacks a natural ligand. HER-2
activation initiates signal cascades including the MAPK
and PI3K/AKT pathways that are essential for cell prolifer-
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ation and differentiation [3]. While the tyrosine kinase
family receptors are found on normal cells, there is evi-
dence that they are overexpressed in many types of
tumours [4-6]. Clinically, c-erbB-2 amplification and/or
overexpression has been associated with poor prognosis
in a number of tumour types such as breast and ovarian
cancer [4,7]. Pathologic specimens from the National Sur-
gical Adjuvant Breast and Bowel Project protocol B-06
were reviewed and correlated with patients' outcome.
Overall survival was decreased in all HER-2/neu-positive
patients, and those patients having HER-2/neu overex-
pression with a good nuclear grade had a five-fold
increase in mortality rate [8].
Overexpression of the HER-2/neu receptor is detected in
25–35% of human breast cancer patients [4,7]. Treatment
of these patients with Herceptin®, an anti-HER-2 mono-
clonal antibody, has been shown to reduce tumour vol-
ume, to augment the effects of chemotherapy and to
increase survival in primary and metastatic breast cancer
[9,10]. The success of HER-2/neu directed therapy in
breast cancer has lead to evaluations of protein expression
and gene amplification in multiple tumour types, colorec-
tal cancer among others. Herceptin® has been shown to
inhibit colony formation of the HCA-7 colon cancer cell
line and HCA-7 tumour xenografts [11].
Conflicting data exist about the prevalence of HER-2/neu
overexpression in colorectal cancer, which ranges from 0
to 83 % [12-16] as well as the relationship between HER-
2/neu overexpression and clinicopathologic features like
Dukes classification and survival.
The aim of our study was to determine the incidence of
HER-2/neu positivity in colorectal cancers. Furthermore,
we investigated the relationship of the HER-2/neu expres-
sion and patients' survival.
Methods
Patient information
This retrospective study involved 77 specimens of malig-
nant colon lesions of patients who underwent elective sur-
gery for colorectal cancer at the Medical University
Vienna. All patients gave informed consent according to
institutional guidelines (Medical University Vienna) prior
to surgery. Tumours were collected in the Department of
Pathology and staged according to TNM system and the
Dukes classification [17,18]. Patients age, gender, site of
primary tumour, degree of differentiation and stage are
shown in Table 1. Patients were followed up every 3
months including clinical examination, laboratory tests
including CEA, computed tomography of the abdomen
and chest x-ray during the first 2 years after surgery and
thereafter in 6–12 months intervals. Coloscopy was per-
formed at 1-year intervals after resection of the primary.
None of the patients had received prior chemotherapy.
Immunohistochemistry
HER-2/neu immunohistochemistry was performed using
the Hercep-Test Kit (Dako, Glostrup, Denmark) according
to the manufacturer's recommendations. 2 µm tissue sec-
tions were deparaffinized, rehydrated and placed in
DAKO Epitope Retireval Solution for 40 minutes at 90°C,
followed by cooling for 20 minutes at room temperature
and treatment with peroxidase-blocking reagent. After-
wards slides were rinsed and incubated with the primary
antibodies against HER-2/neu for 30 minutes followed by
rinsing the slides and incubation with the DAKO Visuali-
zation Reagent for 30 minutes. After washing, the slides
were incubated in diaminobenzidine for 10 minutes,
counterstained with hematoxylin, de-hydrated and cover
slipped.
Scoring system
Evaluation of the results was done according to the criteria
as recommended by the manufacturer using the scores
from 0 to 3+. Score 0 is defended as no staining at all or
membrane staining in < 10% of tumour cells. Score 1+is
defined as faint/barely perceptable membrane staining in
> 10% of tumour cells. The cells are only sarined in part of
the membrane. 2+is defined as weak to moderate staining
of the entire membrane in > 10% of the tumour cells. And
3+ is defined as strong staining of the entire membrane in
> 10%. Score of 0 indicates a negative tumour, while
scores of 1+, 2+ and 3+ were regarded as positive expres-
sion of c-erbB-2.
Table 1: Patients characteristic
Gender
Male 48
Female 29
Age (years)
Median 52,5 years
Range (range 30–83)
Dukes stage
A3  ( 4  % )
B8  ( 1 0  % )
C 14 (18 %)
D 52 (68 %)
Tumour location
Colon 45
Rectal 30
Both 2
Histological grade
Well 3
Moderate 21
Poor 53BMC Cancer 2006, 6:123 http://www.biomedcentral.com/1471-2407/6/123
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Statistics
Expression of Her-2/neu was assessed with respect to TNM
and Dukes' stage, degree of differentiation, site of primary
tumour and patient gender using the chi-squared test. The
effects of c-erbB-2 on survival were tested using Kaplan-
Meier survival plots and analyzed using the log-rank test.
Significance levels were set at p < 0.05. All statistical anal-
yses were carried out using SPSS for Windows version
11.5.
Results
A total of 77 patients with colorectal cancer were studied.
For detailed patients' characteristics see Table 1. The
median age of our patients, of whom 48 were male, was
52,5 years (range 30–83). The primary tumour site was
the colon in 45 patients, the rectum in 30 patients and 2
patients had synchronous colonic and rectal cancer. Out
of our 77 patients, 3 (4%) had Dukes A carcinoma, 8
(10%) Dukes B, 14 patients (18%) Dukes C and the
majority (52 patients, 68%) Dukes D carcinoma. Histo-
logical grade included well (n = 3), moderate (n = 21) and
poorly differentiated (n = 53) adenocarcinoma.
Immunohistochemistry
The 77 colorectal samples were examined for the presence
of Her-2/neu oncoprotein determined by immunhisto-
chemistry. Out of this 77, 56 samples were Her-2/neu neg-
ative (70%). 20 (26%) showed a barely immunostaining,
only 1 (1%) was moderately and 2 (3%) were strongly
positive (Table 2).
Her-2/neu expression and clinicopathological parameters
The expression of the c-erbB-2 protein was evaluated with
respect to the patient's clinicopathological data. Her-2/
neu staining (moderately and strongly positive) was only
detected in primary tumours of patients with confirmed
metastases in regional lymph nodes or distant organs
(Dukes C or D) whereas tumours that were staged as
Dukes A and B showed only no or barely p185Her-2/neu
immunostaining. There was a trend towards a decreasing
frequency of positive c-erbB-2 tumours from colon to rec-
tum but this was not significant (p = 0.251).
No relationship was found between membranous HER-2
expression and patients' gender, age or differentiation.
We also determined the association between the presence
of Her-2/neu oncoprotein and survival. A difference was
observed between positivity and survival although it was
not significant. The median survival time of patients with
positive p185HER-2/neu immunostaining was 21 months
versus 39 months in patients without HER-2/neu expres-
sion (p = 0.088).
Discussion
The ErbB signaling network is known to influence a wide
range of cellular processes, including proliferation, motil-
ity, and survival [19]. It is known that overexpression of
EGFR often portends a worse prognosis [20,21]. The fre-
quency of positivity appears to increase with clinical stage
of disease. Her-2-neu positivity may thus represent a late
event in the natural history of colorectal cancer and is
associated with a worse prognosis. Overexpression of the
HER-2/neu receptor is detected in 25–35% of human
breast cancer [4,7] but the level and incidence of HER-2
overexpression in primary colon tumours appears to be
different than those observed in breast cancer. Conflicting
data exist about the prevalence of HER-2/neu overexpres-
sion in colorectal cancer which ranges from 0 to 83 % [12-
16]. In our study, we examined 77 colorectal cancer
tumour samples for the presence of Her-2/neu oncopro-
tein by immunhistochemistry. Out of these 77 samples,
56 (70%) were negative. Strong membranous HER-2
staining was only detected in 2 cases (3%). No correlation
could be found between clinicopathological features and
the HER-2/neu overexpression. Similar results are
described in the study of Nathason et al [22]; they exam-
ined HER-2/neu gene amplification in 169 colon cancer
specimens and HER-2/neu protein expression in 139
specimens, where they found HER-2/neu to be overex-
pressed in 5 cases (3.6%) and the gene to be amplified in
4 of these cases (2.4%). The HER-2/neu overexpression or
the gene amplification was also not associated with any
specific clinicopathological features [22]. In another
study, strong membranous HER-2 staining was detected
in only 5% of tumors in 96 primary human colorectal
adenocarcinomas that also showed HER-2 gene amplifica-
tion [23]. In contrast to these results are four studies who
did report an association between Her-2/neu overexpres-
sion and advanced stage, decreased survival or both
[14,15,24,25]. One of the studies by Kapitanovic et al [15]
described a significant correlation between the epidermal
abnormality degree and clinical parameters including
Dukes' stage, relapse-free and postoperative survival.
Our study results indicating a very low rate of HER-2-/neu
positivity and no correlation with clinicopathological fea-
tures might be hampered by the small number of cases
(77 specimens), However, the results are in agreement
with same other larger patient series. In contrast to these
data are the above mentioned four publications. The most
Table 2: Distribution of c-erbB-2 expression in colorectal cancer
Immunohistochemical score n %
05 4 7 0
1+ 20 26
2+ 1 1
3+ 2 3BMC Cancer 2006, 6:123 http://www.biomedcentral.com/1471-2407/6/123
Page 4 of 5
(page number not for citation purposes)
likely reason for this divergency is the technical variability
in the performance of immunhistochemistry. It is well
known that there are pitfalls in immunostaining for HER-
2/neu in breast cancer. Another reason may be due to the
fact, that different antibodies have been used, stressing the
importance of using standardized test systems most nota-
bly in case of therapeutic relevance of the results. Our
results were all confirmed by a pathologist who is special-
ized in immunostaining for HER-2/neu and is a well
known reference pathologist for this tumour entity. The
inclusion of cytoplasmatic positivity in the Hercep-score
in earlier papers may also be responsible for the conflict-
ing results regarding the frequency of Her-2neu expression
in colorectal cancer in the literature.
The c-erbB-e protein expression was observed in colorectal
cancer but rarely in the therapeutic range (2+ and 3+). As
known from studies in Her-2/neu metastatic breast can-
cer, Herceptin®, a HER-2 neutralizing antibody, is only
effective in the therapeutic range. In a study by Ram-
anathan et al [26] Her-2/neu positive patients with
advanced colorectal cancer should receive trastuzumab
(Herceptin® and irinotecan treatment. Of 138 screened
patients Her-2/neu overexpression was only detected in
11 (8%; 2+ in 5 and 3+ in 6 patients), therefore the study
was prematurely closed.
These data are similar to ours and indicate that c-erbB-2 is
unlikely to play a major role in the therapeutic manage-
ment of colorectal cancer. Therefore, further investiga-
tions of regimens involving trastuzumab seem not be
useful.
Conclusion
Overexpression of the HER-2/neu receptor is detected in
25–35% of human breast cancer [4,7] but conflicting data
exist about the prevalence of HER-2/neu overexpression
in colorectal cancer ranging from 0 to 83 %. In our study
we analyzed 77 specimens of malignant colorectal cancer
lesions. In only 4 % (3 specimens) the c-erbB protein
expression was observed in the therapeutic range (2+ and
3+), 70% were Her-2/neu negative and 26% showed a
barely immunostaining (1+). There was no significant
association with tumour grade, gender, localization of the
primary tumour or survival. These data indicate that c-
erbB-2 is unlikely to play a major role in the therapeutic
management of colorectal cancer.
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